Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Jon Soderstrom retires from Yale OCR

Jon Soderstrom is stepping down June 30 as managing director of the Yale Office of Cooperative Research. Through the remainder of the year he will serve as...

| By Kelley Gipson

New property counsel team at UConn TCS

With innovation becoming ever more prominent a feature of higher education, UConn Technology Commercialization Services (TCS) recently hired two in-house patent counsels to help inventors...

| By Kelley Gipson

Reflections on BI’s 50 years in the United States

In a recent interview, Jean-Michel Boers, President and CEO of Boehringer Ingelheim USA, spoke of Boehringer Ingelheim’s future as it marks 50 years in the United...

| By Kelley Gipson

Halda Therapeutics opens at Winchester Works

Biotech company Halda Therapeutics has celebrated its new home at Winchester Works in New Haven with a ribbon cutting ceremony and tours. Craig Crews, a Yale...

| By Kelley Gipson

Pierce Laboratory to open new space in New Haven

The John B. Pierce Laboratory has announced it will be opening a new incubator for Connecticut bioscience startups in downtown New Haven this October. Located...

| By Kelley Gipson

CaroGen partners with BioCentriq re hepatitis B

CaroGen Corporation has selected BioCentriq™ as their partner for clinical manufacturing to support Phase 1 clinical trials of its lead immunotherapy candidate, CARG-201, which has...

| By Kelley Gipson

UConn receives record research grant from NSF

The U.S. National Science Foundation (NSF) has awarded the University of Connecticut a $40 million research grant award, the largest in the University’s history, to...

| By Kelley Gipson

MannKind adding Danbury jobs re Tyvaso DPI

MannKind says that its Danbury facility is hiring more than 100 people and is preparing essential equipment and production lines ahead of an expected commercial launch....

| By Kelley Gipson

SpringWorks re glioma, neurofibromas, myeloma

SpringWorks Therapeutics reports the initiation of a Phase 1/2 clinical trial to evaluate mirdametinib, an investigational MEK inhibitor, for the treatment of children, adolescents, and...